The role of bisphosphonates in the management of metastatic prostate cancer.
Authors:
- M. Dror MichaelsonMMM. Dror Michaelson
- Matthew R. SmithMSMatthew R. Smith
- 1 June 2003
- journal article
- review article
- Published by Springer Nature in Current Oncology Reports
- Vol. 5 (3) , 245-249
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and PainJournal of Clinical Oncology, 2003
- Osteoporosis in Men Treated With Androgen Deprivation Therapy for Prostate CancerJournal of Urology, 2002
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Adjuvant bisphosphonate therapy: The futureSeminars in Oncology, 2001
- Treatment of Osteoporosis with BisphosphonatesRheumatic Disease Clinics of North America, 2001
- INCIDENCE OF SKELETAL COMPLICATIONS IN PATIENTS WITH BONE METASTATIC PROSTATE CANCER AND HORMONE REFRACTORY DISEASE: PREDICTIVE ROLE OF BONE RESORPTION AND FORMATION MARKERS EVALUATED AT BASELINEJournal of Urology, 2000
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Disodium Pamidronate Identifies Differential Osteoclastic Bone Resorption in Metastatic Prostate CancerBritish Journal of Urology, 1992
- Morphometric Evidence for Bone Resorption and Replacement in Prostate CancerBritish Journal of Urology, 1991